Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kreutzer, TC; Alge, CS; Wolf, AH; Kook, D; Burger, J; Strauss, R; Kunze, C; Haritoglou, C; Kampik, A; Priglinger, S.
Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.
Br J Ophthalmol. 2008; 92(3):351-355
Doi: 10.1136/bjo.2007.123513
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Strauß Rupert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch retinal vein occlusion. Methods: A prospective, non-comparative, consecutive, interventional case series of 34 patients. Patients received repeated intravitreal injections of 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts and ETDRS) and retinal thickness (optical coherence tomography measurements) in a follow-up period of 6 months. Results: Patients presented at a mean age of 69 years (range 44-86). Mean duration of symptoms was 40 weeks (range 1-300). Mean (SD) VA at baseline was 0.79 (0.39) logMAR, improving to 0.51 (0.34) logMAR at 6 months (p = 0.009). Mean number of letters on the ETDRS chart at baseline was 45.3 (19.0), improving to 60.6 (19.9) at 6 months (p = 0.003). Mean (SD) retinal thickness at baseline was 474 (120) mm, declining to 316 (41) mm at 6 months. Conclusion: Intravitreal injection of 1.25 mg bevacizumb appears to be an effective treatment option for branch retinal vein occlusion.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Angiogenesis Inhibitors - administration and dosage Angiogenesis Inhibitors - therapeutic use
- Antibodies, Monoclonal - administration and dosage Antibodies, Monoclonal - therapeutic use
- Antibodies, Monoclonal, Humanized -
- Drug Administration Schedule -
- Female -
- Fovea Centralis - pathology
- Humans -
- Injections -
- Macular Edema - drug therapy Macular Edema - etiology Macular Edema - pathology Macular Edema - physiopathology
- Male -
- Middle Aged -
- Retinal Vein Occlusion - complications Retinal Vein Occlusion - pathology Retinal Vein Occlusion - physiopathology
- Treatment Outcome -
- Vascular Endothelial Growth Factor A - antagonists and inhibitors
- Visual Acuity - drug effects
- Vitreous Body -